EU’s Avastin Policy: A Stark Contrast To The FDA’s Recent DecisionThe Wall Street Journal: EU Backs Avastin For Breast Cancer
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients. While the FDA plans to revoke approval of Avastin, the U.S. regulator has granted Roche a hearing later this year, though analysts say the Swiss drug maker is unlikely to change the U.S. watchdog's views (Mijuk, 3/2). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.